The influence of body mass index on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in women with early-stage breast cancer

In recent decades there is an immense rise in prevalence of overweight and obesity. According to the World Health Organization more than 650 million adults are obese, which is 13% of the world population [1]. Obesity is a strong predictor of worse health outcomes in different diseases and can also complicate drug dosing [2, 3].

For chemotherapy, it was common use to empirically lower the full-weight-based dosage in obese patients, which is also known as dose capping [4]. One of the reasons to perform dose capping in obese patients is to prevent excessive toxicity [5]. However, there was no evidence that toxicity was increased among obese patients receiving full-weight-based chemotherapy doses, while some studies do suggest compromised survival outcomes due to dose capping [4, 6‐11]. Therefore, a clinical practice guideline was released in 2012 by the American Society of Clinical Oncology (ASCO) recommending to use full-weight-based chemotherapy doses in obese patients [12]. As this guideline has been updated last year with additional recommendations for immunotherapy and targeted therapy dosing, the recommendations for chemotherapy dosing remained unchanged [13].

A recent study in early breast cancer patients showed that obese patients treated with adjuvant docetaxel-containing chemotherapy received a lower relative dose intensity (RDI) compared to lean patients, while no upfront dose capping was applied in obese patients due to excess weight. In addition, obese patients had a shorter disease-free survival and overall survival compared to lean patients, which was also the case when only patients with a RDI of 85% or higher were analyzed. Therefore, it appears that obese patients tolerate full-weight-based docetaxel chemotherapy less well compared to lean patients, which negatively influences survival outcomes. These trends were not observed in patients who received non-docetaxel chemotherapy, suggesting a differential response to docetaxel according to body mass index (BMI) [14].

As obesity has become increasingly common and adjuvant chemotherapy with taxanes in early breast cancer is a cornerstone of the treatment, it is important to study whether these findings for docetaxel are also observed for paclitaxel chemotherapy. Therefore, the aim of this study was to investigate the influence of BMI on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in early breast cancer patients.

This retrospective observational cohort study was conducted at the Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital (NKI-AvL), Amsterdam, the Netherlands. Patients diagnosed with early breast cancer between January 2016 and July 2020, who received paclitaxel 80 mg/m² in a weekly regimen as (neo)adjuvant treatment were included in this study. Only patients with estrogen receptor-positive (ER+) and/or human epidermal growth receptor 2-positive (HER2+) breast cancer were included. Patients with triple-negative breast cancer were excluded as they receive a combination of paclitaxel and carboplatin at our institute. Patients with ER+/Her2− breast cancer received doxorubicin 60 mg/m² with cyclophosphamide 600 mg/m² every 2 or 3 weeks for four cycles followed by paclitaxel 80 mg/m² weekly for 12 cycles. Patients with cT1N0 Her2+ breast cancer received paclitaxel 80 mg/m² weekly for 12 cycles as chemotherapy, in combination with trastuzumab with a loading dose of 300 mg, followed by 150 mg every week during the paclitaxel chemotherapy. Trastuzumab treatment in these patients continued up to 1 year, in which 450 mg was administered every 3 weeks. Before August 2017, a loading dose of 4 mg/kg trastuzumab was used, whereas during following cycles a dose of 2 mg/kg was administered every week, followed by 6 mg/kg trastuzumab every other 3 weeks up to 1 year.

Data on patient characteristics, tumor characteristics, treatments, and toxicity were extracted from the electronic medical record (EMR) HiX (ChipSoft, Amsterdam, the Netherlands). The conduct of this observational study was approved by the Investigational Review Board of the NKI-AvL and the need for written informed consent was waived.

Patients were categorized into three groups based on their BMI according to the categories of the World Health Organization: underweight (< 18.5 kg/m²), lean (≥ 18.5 and < 25 kg/m²), overweight (≥ 25 and < 30 kg/m²), and obese (≥ 30 kg/m²). Underweight patients were excluded from this study due to a low frequency (n = 3). BMI for each patient was calculated as the median of all BMI measurements during the course of chemotherapy treatment. Chemotherapy doses for each patient could change during the course of chemotherapy treatment according to weight changes and were determined by calculating the body surface area (BSA) using the formula of DuBois [15].

Study outcomes were the occurrence of dose capping and the median-administered RDI. In addition, it was determined how often treatment modifications occurred and what toxicity caused these modifications. For patients who received neoadjuvant chemotherapy, the pathological response of the tumor to chemotherapy treatment was also assessed as a surrogate endpoint for effectiveness.

RDI is calculated using the following formula:

The standard total dose was the amount of drug patients would receive if all chemotherapy courses were administered according to the calculated BSA. Time to complete the chemotherapy was defined as the time from the first day of the first cycle until the last day of the last cycle. The standard time to complete the described paclitaxel chemotherapy regimen was 84 days. If less than 12 cycles were administered and the determined time to complete the chemotherapy was shorter than 84 days, this was increased to 84 days as imputation for missed cycles.

Descriptive statistics were reported using frequencies for categorical data and means for continuous data. Categorical variables between BMI categories were compared with Fisher’s exact test. Continuous variables between BMI categories were compared using the ANOVA test or the Kruskal–Wallis test, depending on the appropriateness of the tests. Multivariable logistic regression was performed to assess association between BMI and administered RDI < 85% while adjusting for confounders. Two-sided p values < .05 were considered significant. All statistical analyses were performed in R version 4.0.4 (R Foundation for Statistical Computing, Vienna, Austria).

This study investigated whether dose capping still occurred in clinical practice and what the influence of BMI was on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in early breast cancer patients. None of the patients had their chemotherapy doses capped due to excess weight. There were only small differences observed in the administered RDI of paclitaxel chemotherapy, which were not of clinical significance, in contrast to the results of the study of Desmedt et al. for docetaxel chemotherapy [14]. In a recent study, no significant difference in pharmacokinetic parameters for paclitaxel was observed between lean, overweight, and obese patients, supporting the results in our study [16]. In contrast, the volume of distribution and half-life of docetaxel were significantly increased in obese patients [17].

Although no significant differences were observed in administered RDIs between the different BMI categories, there were differences observed in the type of toxicity leading to chemotherapy treatment modifications. Various studies have already shown that a higher BMI, higher fat mass, or lower skeletal muscle mass are associated with an increased risk and severity of toxicity [18‐20]. In line with these results, peripheral neuropathy leading to treatment modifications was observed more frequent in obese patients, although not statistically significant. From other studies, it appeared that the risk of paclitaxel-induced peripheral neuropathy is higher in older patients with estrogen decline [21, 22]. As the patients in the obese group in our study were relatively older and more often postmenopausal, these observations may be related to one another.

The risk of hematologic toxicities decreased significantly with an increasing BMI in our study. Studies investigating toxicity of chemotherapy in breast cancer patients show different results as some found no difference, a lower risk, or even a higher risk of hematologic toxicity in obese patients compared to lean patients [5, 23‐25]. It has to be noted that chemotherapy regimens in these studies differed, which may explain the differences observed in these studies. A potential explanation for the decreased risk of hematologic toxicity in obese patients is the presence of chronic inflammation leading to increased neutrophil counts [26‐28].

An exploratory analysis of the NeoALTTO trial reported lower pCR rates in overweight and obese patients with hormone-positive and Her2+ breast cancer, compared to underweight and lean patients, whereas this trend was not observed in patients with hormone-negative and Her2+ breast cancer [29]. Wang et al. performed a meta-analysis investigating the impact of BMI on pCR after neoadjuvant chemotherapy in early breast cancer patients. They found that overweight and obese breast cancer patients had lower pCR rates compared to underweight or lean patients. However, in some of the included studies dose capping was performed, whereas for seven of the thirteen included studies, no information on chemotherapy dosing was provided [30]. One of the included studies in this meta-analysis showed that a lower RDI of taxanes resulted in a lower pCR rate [31]. In another study performed by Farr et al., obese women receiving full-weight based chemotherapy even had increased pCR rates and a more favorable progression-free survival compared to lean and overweight patients [32]. In our study, no significant differences were observed in pCR between the BMI categories, which is potentially due to the fact that there were no significant differences in administered RDI between BMI categories.

The main limitation of this study is its retrospective approach, making us dependent on the information that is captured in the electronic medical records. For example, the grading of the toxicity leading to chemotherapy dose reductions, dose delays, or cancellations was often absent. However, the specific adverse events leading to chemotherapy dose modifications was well documented. Another limitation is the relatively low number of obese patients in our study, which is in particular the case in the analysis of pathological response. In addition, BMI may not be the most optimal measure to determine toxicity and survival, as it does not distinguish between muscle and fat mass [18, 19, 33]. Therefore, further research on the influence of obesity on chemotherapy treatment, in which fat mass is determined by CT scans, would be of interest.

In conclusion, BMI did not significantly influence the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy. Therefore, the results of this study align with current guideline recommendations of using full-weight-based paclitaxel chemotherapy in obese patients.